Trials / NCT00029289
Effects of Lutein in Retinitis Pigmentosa
Completed Phase 1 / Phase 2 Supplement / diet, Drug / neuroprotection
- Sponsor
- National Center for Complementary and Integrative Health (NCCIH)
- Treatment
- Lutein (10 or 30 mg/day) capsules
- Gene
- Not stated
- Conditions
- Retinitis Pigmentosa
- Ages
- Any to no upper limit
- Enrollment
- Not stated participants
- Started
- 2001-04
- Main results expected
- Not stated
- Results posted
- Not yet
- Record last updated
- 2006-08-18
What the study is testing
Phase I/II double-masked, randomized, placebo-controlled, cross-over trial to determine effects of lutein on vision in retinitis pigmentosa, including safety and effective dosage assessment
Where it runs
United States (1)
- Johns Hopkins Wilmer Eye Institute, Lions Vision Center, Baltimore, Maryland